Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

  • Details

ClinicalTrials.gov ID: NCT02947347
Diagnosis Type: Non-Hodgkins
USOR Number: 16176

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Allen

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: NA
USOR Number: 17079

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Plano

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Plano

BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant,hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments (CBYL719X2402)

  • Details

ClinicalTrials.gov ID: NCT03056755
Diagnosis Type: NA
USOR Number: 17026

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Plano

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Plano

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Plano

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Plano

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Essential Thrombocythemia

Clinical Trial at: Texas Oncology - Plano

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Plano

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Plano

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Plano

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Plano

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

3705 West 15th Street
Plano, Texas 75075
287.21 mi. away
P: (972) 867-3577

More Details View Practice Page

Pages